Abstract
Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.
Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.
Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.
Keywords: Chronic kidney disease, diabetes mellitus, diabetic nephropathy, end stage renal disease, novel therapies.
Current Drug Metabolism
Title:Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies
Volume: 17 Issue: 5
Author(s): Riccardo Pofi, Francesca Di Mario, Antonietta Gigante, Edoardo Rosato, Andrea M. Isidori, Antonio Amoroso, Rosario Cianci and Biagio Barbano
Affiliation:
Keywords: Chronic kidney disease, diabetes mellitus, diabetic nephropathy, end stage renal disease, novel therapies.
Abstract: Background: Diabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.
Methods: Treatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.
Conclusion: The purpose of this review is to summarize the “state of art” of current novel therapeutic strategies to stem this debilitating kidney disease.
Export Options
About this article
Cite this article as:
Pofi Riccardo, Di Mario Francesca, Gigante Antonietta, Rosato Edoardo, Isidori M. Andrea, Amoroso Antonio, Cianci Rosario and Barbano Biagio, Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies, Current Drug Metabolism 2016; 17 (5) . https://dx.doi.org/10.2174/138920021705160324165553
DOI https://dx.doi.org/10.2174/138920021705160324165553 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
Current Vascular Pharmacology Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus and Renal Function: Current Medical Research and Opinion
Current Diabetes Reviews Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Renin–Angiotensin–Aldosterone System Gene Polymorphisms and Type 2 Diabetic Nephropathy in Asian Populations: An Updated Meta-analysis
Current Diabetes Reviews Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Antioxidants in the Treatment of Diabetes
Current Diabetes Reviews Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design